"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 0 | 2 | 2 |
| 2005 | 3 | 2 | 5 |
| 2006 | 0 | 3 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 2 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 0 | 8 | 8 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 6 | 7 |
| 2016 | 3 | 4 | 7 |
| 2017 | 3 | 5 | 8 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 6 | 10 |
| 2020 | 4 | 1 | 5 |
| 2021 | 3 | 8 | 11 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 5 | 5 |
| 2024 | 4 | 6 | 10 |
| 2025 | 2 | 3 | 5 |
| 2026 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Circulating Tumor DNA in Head and Neck Cancer: A Review From the American Head and Neck Society. JAMA Otolaryngol Head Neck Surg. 2026 Sep 01; 152(9):905-913.
-
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. J Natl Compr Canc Netw. 2026 Jun; 24(6):222-229.
-
The Natural History of Residual and Recurrent Disease in Advanced Juvenile Nasopharyngeal Angiofibroma: A Systematic Review. Laryngoscope. 2026 Oct; 136(10):4130-4138.
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
-
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. Clin Cancer Res. 2026 Feb 04; 32(3):479-488.
-
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time? Hematology Am Soc Hematol Educ Program. 2025 12 05; 2025(1):645-651.
-
Postoperative Human Papilloma Virus Circulating Tumor DNA Guided Adjuvant Therapy for Human Papilloma Virus-Related Oropharyngeal Carcinoma (PATH Study). Int J Radiat Oncol Biol Phys. 2026 03 01; 124(3):676-685.
-
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy. Drugs. 2025 Oct; 85(10):1231-1251.
-
The role of maintenance therapy and its cessation in patients with multiple myeloma. Leuk Lymphoma. 2025 Dec; 66(13):2426-2436.
-
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025 Mar 25; 9(6):1442-1451.